CRYSTALLINE FORM OF RIVAROXABAN DIHYDRATE
    1.
    发明申请
    CRYSTALLINE FORM OF RIVAROXABAN DIHYDRATE 有权
    RIVAROXABAN DIHYDRATE的结晶形式

    公开(公告)号:US20130245017A1

    公开(公告)日:2013-09-19

    申请号:US13805462

    申请日:2011-07-05

    IPC分类号: C07D413/12

    CPC分类号: C07D413/12 C07D413/14

    摘要: The present invention relates to a novel crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline dehydrate and to processes for preparing and storing said pharmaceutical compositions. The invention also relates to a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and to the use of said Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.

    摘要翻译: 本发明涉及一种新型的Rivaroxaban结晶二水合物,其制备方法,包含所述结晶脱水物的药物组合物以及制备和储存所述药物组合物的方法。 本发明还涉及Rivaroxaban的结晶甲酸溶剂化物,制备结晶Rivaroxaban甲酸溶剂合物的方法,以及所述Rivaroxaban甲酸溶剂合物在制造Rivaroxaban结晶二水合物中的用途。

    ORGANIC COMPOUNDS
    3.
    发明申请
    ORGANIC COMPOUNDS 审中-公开
    有机化合物

    公开(公告)号:US20110015191A1

    公开(公告)日:2011-01-20

    申请号:US12528483

    申请日:2008-02-22

    CPC分类号: C07D413/06

    摘要: Novel polymorph form III of Aprepitant and a method for preparation of novel form III is disclosed. New processes for the preparation of Aprepitant form II are disclosed. The processes involve transformation of form III to form II by heating in decalin and the precipitation of form II from a solvent or solvent mixture by cooling and/or addition of addition of seed crystals or an anti solvent. Solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A process for the preparation of the solid dispersion by evaporation of a solution of Aprepitant and the carrier in a suitable solvent is disclosed. Stable Aprepitant form II is disclosed. Further pharmaceutical compositions containing Aprepitant form II, III or solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A methanol solvate of Aprepitant is disclosed.

    摘要翻译: 公开了Aprepitant的新型多晶型III和新型III的制备方法。 公开了制备Aprepitant II型的新方法。 所述方法包括通过在十氢化萘中加热和通过冷却和/或加入晶种或抗溶剂从溶剂或溶剂混合物中沉淀形式II而转化成形式II。 公开了在合适的载体中含有形式II的固体分散体。 公开了通过在适当溶剂中蒸发阿维地丁和载体溶液来制备固体分散体的方法。 公开了稳定的Aprepitant II型。 公开了另外的药物组合物,其中含有Aprepitant形式II,III或在合适的载体中含有Aprepitant II型的固体分散体。 公开了一种甲酸溶剂化物的Aprepitant。

    Amorphous telithromycin compound
    4.
    发明授权
    Amorphous telithromycin compound 失效
    无定型泰利霉素化合物

    公开(公告)号:US08222380B2

    公开(公告)日:2012-07-17

    申请号:US12159939

    申请日:2007-01-04

    IPC分类号: C07H17/08

    CPC分类号: C07H17/08

    摘要: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

    摘要翻译: 本发明涉及稳定的无定形3-De [(2,6-二脱氧-3-C-甲基-3-O-甲基-α-L-核糖-6-吡喃糖基)氧基] -11,12-二脱氧-6-O-甲基 -3-氧代-12,11- [氧羰基[[4- [4-(3-吡啶基)-1H-咪唑-1-基]丁基]亚氨基]]红霉素(泰利霉素),其制备方法, 稳定的非晶泰利霉素治疗细菌感染和包含稳定的非晶泰利霉素的药物组合物。

    Amorphous Telithromycin Compound
    5.
    发明申请
    Amorphous Telithromycin Compound 失效
    无定型泰利霉素化合物

    公开(公告)号:US20080280841A1

    公开(公告)日:2008-11-13

    申请号:US12159939

    申请日:2007-01-04

    CPC分类号: C07H17/08

    摘要: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

    摘要翻译: 本发明涉及稳定的无定形3-De [(2,6-二脱氧-3-C-甲基-3-O-甲基-α-L-核糖-6-吡喃糖基)氧基] -11,12-二脱氧-6-O-甲基 -3-氧代-12,11- [氧羰基[[4- [4-(3-吡啶基)-1H-咪唑-1-基]丁基]亚氨基]]红霉素(泰利霉素),其制备方法, 稳定的非晶泰利霉素治疗细菌感染和包含稳定的非晶泰利霉素的药物组合物。

    CRYSTALLINE FORM OF CINACALCET
    7.
    发明申请
    CRYSTALLINE FORM OF CINACALCET 审中-公开
    CINACALCET的结晶形式

    公开(公告)号:US20090197970A1

    公开(公告)日:2009-08-06

    申请号:US12303411

    申请日:2007-06-25

    IPC分类号: A61K31/137 C07C211/52

    CPC分类号: C07C211/30

    摘要: The present invention relates to the polymorph form II of Cinacalcet hydrochloride, methods for the preparation of pure form II of Cinacalcet hydrochloride, and pharmaceutical compositions comprising the new polymorphic form in an pharmaceutically effective amount The present invention also provides novel solvates of Cinacalcet hydrochloride, methods for the preparation of these solvates, the use of these novel solvates for the preparation of pure Cinacalcet hydrochloride, the use of these novel solvates for the preparation of polymorphic form II of Cinacalcet hydrochloride and pharmaceutical compositions comprising the acetic acid solvate of Cinacalcet hydrochloride.

    摘要翻译: 本发明涉及盐酸西那卡塞的多晶型II,盐酸西那卡塞的纯形式II的制备方法和药物组合物,其含有药学有效量的新型多晶型本发明还提供盐酸西卡西塞的新型溶剂合物,方法 为了制备这些溶剂合物,使用这些新型溶剂合物制备纯的西那卡塞盐酸盐,这些新型溶剂合物用于制备盐酸西那卡塞的多晶型II和包含盐酸西卡西塞的乙酸溶剂化物的药物组合物的用途。

    Salts of aripiprazole
    8.
    发明授权
    Salts of aripiprazole 有权
    阿立哌唑盐

    公开(公告)号:US07884205B2

    公开(公告)日:2011-02-08

    申请号:US11883125

    申请日:2006-01-27

    IPC分类号: C07D401/12 A61K31/497

    CPC分类号: C07D215/227 C07B2200/13

    摘要: The present invention relates to acid addition salts of aripiprazole, a process for preparing said acid addition salts and their use to prepare or purify aripiprazole in the form of a free base or in the form of a pharmaceutically acceptable salt.

    摘要翻译: 本发明涉及阿立哌唑的酸加成盐,制备所述酸加成盐的方法及其用于制备或纯化游离碱形式的阿立哌唑或其药学上可接受的盐形式的用途。

    Salts of Aripiprazole
    9.
    发明申请
    Salts of Aripiprazole 有权
    阿立哌唑盐

    公开(公告)号:US20080287677A1

    公开(公告)日:2008-11-20

    申请号:US11883125

    申请日:2006-01-27

    IPC分类号: C07D401/12

    CPC分类号: C07D215/227 C07B2200/13

    摘要: The present invention relates to acid addition salts of aripiprazole, a process for preparing said acid addition salts and their use to prepare or purify aripiprazole in the form of a free base or in the form of a pharmaceutically acceptable salt.

    摘要翻译: 本发明涉及阿立哌唑的酸加成盐,制备所述酸加成盐的方法及其用于制备或纯化游离碱形式的阿立哌唑或其药学上可接受的盐形式的用途。

    Process for the production of cephalosporines
    10.
    发明授权
    Process for the production of cephalosporines 失效
    生产头孢菌素的方法

    公开(公告)号:US06169180A

    公开(公告)日:2001-01-02

    申请号:US08947215

    申请日:1997-10-08

    IPC分类号: C07D50106

    CPC分类号: C07D501/00 Y02P20/55

    摘要: The invention relates to a new economical and simple process, using a new intermediate compound, for the production of 3′-substituted 7-amino-3-propenyl-4-cephem-carboxylic acid derivatives of formula wherein R is hydrogen, a negative charge or a silyl protecting group, Ro is hydrogen or methoxy, R1 is hydrogen or a silyl protecting group and X is the radical of a nucleophile, and their acid addition salts.

    摘要翻译: 本发明涉及一种新的经济和简单的方法,使用新的中间体化合物,用于生产糠醛的3'-取代的7-氨基-3-丙烯基-4-头孢烯羧酸衍生物,R是氢,负电荷或 甲硅烷基保护基,Ro是氢或甲氧基,R1是氢或甲硅烷基保护基,X是亲核试剂的基团,以及它们的酸加成盐。